MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
67.15
-1.30
-1.90%
Opening 12:31 05/29 EDT
OPEN
67.96
PREV CLOSE
68.45
HIGH
68.15
LOW
66.76
VOLUME
995.12K
TURNOVER
--
52 WEEK HIGH
84.94
52 WEEK LOW
31.77
MARKET CAP
13.15B
P/E (TTM)
-17.9267
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio price target raised to $98 from $94 at Morgan Stanley
TipRanks · 1d ago
BridgeBio Pharma Price Target Raised to $98.00/Share From $94.00 by Morgan Stanley
Dow Jones · 1d ago
BridgeBio Pharma Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $98
Benzinga · 1d ago
BridgeBio Pharma Price Target Maintained With a $110.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), BridgeBio Pharma (BBIO)
TipRanks · 1d ago
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $110 Price Target
Benzinga · 1d ago
Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data
TipRanks · 1d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.